Cosmo Pharmaceuticals Launches Winlevi® in Singapore and Malaysia, Expanding Acne Treatment in Southeast Asia

Reuters

Jul 17

Cosmo Pharmaceuticals Launches Winlevi® in Singapore and Malaysia, Expanding Acne Treatment in Southeast Asia

Cosmo Pharmaceuticals N.V. has announced the launch of Winlevi® (clascoterone) cream 1% in Singapore and Malaysia, marking its entry into Southeast Asia through a partnership with Hyphens Pharma International Limited. This topical treatment for acne vulgaris is aimed at patients aged twelve and older. The collaboration is part of Cosmo's strategy to expand its global reach and address the increasing demand for advanced acne care in the region. This launch is a significant step towards offering innovative dermatology solutions and improving the quality of life for millions affected by acne.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmo Pharmaceuticals NV published the original content used to generate this news brief on July 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2552108304"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552108304\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2552108304?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-17 13:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552108304","market":"nz","top_or_hot":-1,"title":"Cosmo Pharmaceuticals Launches Winlevi® in Singapore and Malaysia, Expanding Acne Treatment in Southeast Asia","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cosmo Pharmaceuticals Launches Winlevi® in Singapore and Malaysia, Expanding Acne Treatment in Southeast Asia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cosmo Pharmaceuticals N.V. has announced the launch of Winlevi® (clascoterone) cream 1% in Singapore and Malaysia, marking its entry into Southeast Asia through a partnership with Hyphens Pharma International Limited. This topical treatment for acne vulgaris is aimed at patients aged twelve and older. The collaboration is part of Cosmo's strategy to expand its global reach and address the increasing demand for advanced acne care in the region. This launch is a significant step towards offering innovative dermatology solutions and improving the quality of life for millions affected by acne.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CMOPF\">Cosmo Pharmaceuticals NV</a> published the original content used to generate this news brief on July 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cosmo Pharmaceuticals Launches Winlevi® in Singapore and Malaysia, Expanding Acne Treatment in Southeast Asia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCosmo Pharmaceuticals Launches Winlevi® in Singapore and Malaysia, Expanding Acne Treatment in Southeast Asia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-17 13:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cosmo Pharmaceuticals Launches Winlevi® in Singapore and Malaysia, Expanding Acne Treatment in Southeast Asia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cosmo Pharmaceuticals N.V. has announced the launch of Winlevi® (clascoterone) cream 1% in Singapore and Malaysia, marking its entry into Southeast Asia through a partnership with Hyphens Pharma International Limited. This topical treatment for acne vulgaris is aimed at patients aged twelve and older. The collaboration is part of Cosmo's strategy to expand its global reach and address the increasing demand for advanced acne care in the region. This launch is a significant step towards offering innovative dermatology solutions and improving the quality of life for millions affected by acne.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CMOPF\">Cosmo Pharmaceuticals NV</a> published the original content used to generate this news brief on July 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK6079","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250717:nNDL3L97QG:1","article_id":"2552108304","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552108304","pubTimestamp":1752728782,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cosmo Pharmaceuticals N.V. has announced the launch of Winlevi  cream 1% in Singapore and Malaysia, marking its entry into Southeast Asia through a partnership with Hyphens Pharma International Limited. This topical treatment for acne vulgaris is aimed at patients aged twelve and older. The collaboration is part of Cosmo's strategy to expand its global reach and address the increasing demand for advanced acne care in the region. This launch is a significant step towards offering innovative dermatology solutions and improving the quality of life for millions affected by acne.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmo Pharmaceuticals NV published the original content used to generate this news brief on July 17, 2025, and is so","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK6079":"制药","BK6506":"制药与医学研究概念","1J5.SI":"凯帆药剂国际有限公司"},"translate_title":"科斯莫制药推出Winlevi®在新加坡和马来西亚，扩大东南亚痤疮治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"1J5.SI":0.9},"content_text":"Cosmo Pharmaceuticals Launches Winlevi® in Singapore and Malaysia, Expanding Acne Treatment in Southeast Asia\n    \n\n        Cosmo Pharmaceuticals N.V. has announced the launch of Winlevi® (clascoterone) cream 1% in Singapore and Malaysia, marking its entry into Southeast Asia through a partnership with Hyphens Pharma International Limited. This topical treatment for acne vulgaris is aimed at patients aged twelve and older. The collaboration is part of Cosmo's strategy to expand its global reach and address the increasing demand for advanced acne care in the region. This launch is a significant step towards offering innovative dermatology solutions and improving the quality of life for millions affected by acne.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmo Pharmaceuticals NV published the original content used to generate this news brief on July 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}